FRONTERA GROUP is a cross-functional blend of behaviour and creative engagement experts. Our approach identifies the underlying drivers of decision making, to uncover how choices are made today and ...

A dynamic medical communications agency helping innovative life sciences companies to Be Heard, Be Understood & Be the Difference.

Novo Nordisk has shared promising results from a late-stage study of semaglutide in patients with metabolic ...

The National Institute for Health and Care Excellence (NICE) has recommended Blueprint Medicines’ Ayvakyt (avapritinib) to ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission (EC) to treat eosinophilic ...

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...

EatMoreFruit, a UK top 10 independent healthcare communication agency, today announced the launch of its European Network to ...

AstraZeneca’s Fasenra (benralizumab) has been approved by the European Commission (EC) to treat eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune-mediated inflammatory disease that ...

GCI Health has announced the appointment of Annalise Coady as president, UK market lead and EMEA head of growth. Coady brings over two decades of experience in building and scaling marketing ...

Johnson & Johnson (J&J) has announced that its pan-FGFR tyrosine kinase inhibitor Balversa (erdafitinib) has been granted marketing authorisation by the Medicines and Healthcare products Regulatory ...

The US Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi (minocycline hydrochloride extended release capsules 40mg) to treat inflammatory lesions of rosacea in adults. Affecting ...